当前位置：
X-MOL 学术
›
ChemMedChem
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Front Cover: Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic Evaluation (ChemMedChem 11/2020)
ChemMedChem ( IF 3.6 ) Pub Date : 2020-05-18 , DOI: 10.1002/cmdc.202000315 Rita Maria Concetta Di Martino 1 , Giovanni Bottegoni 2 , Francesca Seghetti 3 , Debora Russo 4 , Ilaria Penna 4 , Alessio De Simone 5 , Giuliana Ottonello 6 , Sine Mandrup Bertozzi 6 , Andrea Armirotti 6 , Tiziano Bandiera 4 , Federica Belluti 3 , Andrea Cavalli 1, 3
ChemMedChem ( IF 3.6 ) Pub Date : 2020-05-18 , DOI: 10.1002/cmdc.202000315 Rita Maria Concetta Di Martino 1 , Giovanni Bottegoni 2 , Francesca Seghetti 3 , Debora Russo 4 , Ilaria Penna 4 , Alessio De Simone 5 , Giuliana Ottonello 6 , Sine Mandrup Bertozzi 6 , Andrea Armirotti 6 , Tiziano Bandiera 4 , Federica Belluti 3 , Andrea Cavalli 1, 3
Affiliation
|
The Front Cover summarizes the idea of developing molecules potentially active in the treatment of bipolar disorder, a mental condition in which episodes of mania alternate with depression. Within the framework of polypharmacology, the authors have rationally developed compounds that concurrently modulate two targets implicated in bipolar disorder: the dopamine receptor D3 and glycogen synthase kinase 3β. More information can be found in the Communication by Federica Belluti, Andrea Cavalli et al.
中文翻译：
封面：双相障碍的多靶标化合物：从合理设计到药代动力学初步评估（ChemMedChem 11/2020）
封面总结了开发在双相情感障碍（一种躁狂发作与抑郁交替发作的精神状态）的治疗中可能具有活性的分子的想法。在多元药理学的框架内，作者合理开发了可同时调节与躁郁症有关的两个靶标的化合物：多巴胺受体D3和糖原合酶激酶3β。有关更多信息，请参见Federica Belluti的通讯，Andrea Cavalli等人。
更新日期：2020-05-18
中文翻译：
封面：双相障碍的多靶标化合物：从合理设计到药代动力学初步评估（ChemMedChem 11/2020）
封面总结了开发在双相情感障碍（一种躁狂发作与抑郁交替发作的精神状态）的治疗中可能具有活性的分子的想法。在多元药理学的框架内，作者合理开发了可同时调节与躁郁症有关的两个靶标的化合物：多巴胺受体D3和糖原合酶激酶3β。有关更多信息，请参见Federica Belluti的通讯，Andrea Cavalli等人。
京公网安备 11010802027423号